A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma

Trial Profile

A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Radium 223 chloride (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 06 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as study restarted under new study number 18987
    • 20 May 2016 Protocol has been amended to change in treatment table by adding SOC bortezomib/dexamethasone to all the treatment arms.
    • 20 May 2016 Planned End Date changed to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top